Becton, Dickinson and Company reported higher revenue and stronger cash generation for fiscal 2026, its first full year after completing the separation of its Life Sciences business. The company said its fourth-quarter growth was broad-based and highlighted a new U.S. government partnership involving a multiyear domestic investment commitment.
BD also issued fiscal 2027 guidance, though the figures are not included in the materials provided here.
Key details
- Fourth-quarter revenue reached $5.3 billion, up 5.4% from a year earlier, or 5.6% excluding currency effects.
- Fourth-quarter diluted earnings per share were $2.52 on a GAAP basis and $4.15 on an adjusted basis.
- For fiscal 2026, revenue was $19.5 billion, an increase of 4.9% as reported and 3.9% excluding currency effects.
- Full-year diluted earnings per share were $5.06 on a GAAP basis and $12.70 on an adjusted basis. The release’s headline figures do not explain the difference between the two measures.
- Cash generation improved: cash from continuing operations rose 30.0% to $3.6 billion, while free cash flow increased 42.5% to $2.9 billion.
- BD said it completed its transformation into a more focused medical-technology company with the separation of its Life Sciences business. CEO Tom Polen described the year as a turning point and said the company had strengthened its growth platforms, commercial capabilities and productivity efforts.
- The company plans to invest $19 billion in the United States over several years under a partnership with the U.S. government. The planned spending includes capital, operating and supply-chain investments, with $3 billion earmarked for manufacturing expansion aimed at supporting supplies of essential medical consumables.
- The agreement provides relief from future tariffs imposed under Section 232 on covered BD products and inputs. That relief is subject to the eventual scope and implementation of future tariff actions, as well as BD meeting agreed milestones.
- In a healthcare-automation initiative, Fairview Health Services became the first U.S. health system to deploy BD’s Vmax 160 pharmacy automation robot. The system is designed to handle specialty therapies and refrigerated medicines in high-volume outpatient pharmacies, in addition to traditional dispensing.
Plain-English implications
The Life Sciences separation leaves BD positioned as a more focused MedTech company, while the government partnership commits substantial spending to U.S. operations and manufacturing. The tariff relief is not unconditional: it depends on future policy details and BD meeting the partnership’s milestones.